| Literature DB >> 29940982 |
Jayaweera Arachchige Asela Sampath Jayaweera1, Mohommed Reyes2.
Abstract
BACKGROUND: In children, urinary tract infection (UTI) is one of a common bacterial infection. This study was conducted to detect the uropathogen, antimicrobial susceptibility, pathogen associated with recurrences and renal scarring in children initially taken care from general practitioners and later presented to tertiary care.Entities:
Keywords: Bio film; Childhood UTI; Emergence of resistance; Empiric antimicrobial; General practitioner; Recurrent pyelonephritis and renal scarring
Mesh:
Substances:
Year: 2018 PMID: 29940982 PMCID: PMC6016131 DOI: 10.1186/s12941-018-0279-4
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Demography and clinical presentation data in study cohort
| Parameter | Frequency % (n = 220) | Comments and p value |
|---|---|---|
| Age | ||
| 1– ≤ 12 months | 50% (n = 110) | Occurrence of UTI is significantly high among infants (p = 0.03) |
| ≥ 12–60 months | 26% (n = 57) | |
| ≥ 60 months–12 years | 24% (n = 53) | |
| Sex male: female in; | ||
| 1–≤ 12 months | 40:60 | After 5 years of age male predominance was observed (p = 0.03) |
| ≥ 12–60 months | 42:58 | |
| ≥ 60 months–12 years | 54:46 | |
| Ethnicity | ||
| Sinhala | 65% | |
| Sri Lankan Moor | 26% | |
| Sri Lankan Tamil | 8% | |
| Other | 1% | |
| Clinical presentation-prominent | ||
| Excessive crying | 7% | The most prominent clinical presentation/s were given and overlapping of symptoms were observed |
| Fever | 68% | |
| Vomiting | 36% | |
| Crying during micturition | 28% | |
| Crying prior to micturition | 24% | |
| Crying after micturition | 27% | |
| Hematuria | 22% | |
| Dysuria | 32% | |
| Frequency | 32% | |
| Loin pain | 26% | |
| Supra-pubic pain | 23% | |
| Drowsy | 4% | |
Detail of past infections in period of 6 months, use of antimicrobials, about the current episode including treatment and inward investigation profile and follow up for next 18 months in patients with UTI
| Parameter | Frequency (%) in age categories (n = 220) | p value | ||
|---|---|---|---|---|
| 1–≤ 12 months | ≥ 12–60 months | ≥ 60 months–12 years | ||
| Past clinical history (6 months)-conditions to seek antimicrobial medications | ||||
| UTI | 56 (50.1) | 34 (59.6) | 24 (45.1) | p = 0.03 |
| ARTI | 66 (0.6) | 45 (78.9) | 30 (56.6) | p = 0.03 |
| AGE | 32 (29.1) | 14 (24.6) | 14 (26.4) | – |
| Infection in CNS | 4 (3.6) | 6 (10.5) | 12 (22.6) | – |
| IE | – | 1 (1.7) | 2 (3.7) | – |
| Abscess | 12 (10.9) | 10 (17.5) | 12 (22.6) | – |
| Accidental wounds | 3 (2.7) | 12 (21) | 23 (43.3) | p = 0.02 |
| Use of antimicrobials | 100% | 100% | 100% | – |
| ICU admissions | 3 (2.7) | 3 (5.2) | 4 (7.5) | – |
| Commonly used antimicrobials in last 6 months | ||||
| Beta-lactams | ||||
| Penicillin | 4 (7.2) | 8 (21) | 3 | – |
| Cephalosporin | 43 | 31 | 30 | p = 0.02 |
| Cefuroxime | 4 | 5 | 3 | – |
| Ceftriaxone | 9 | 4 | 4 | – |
| Cefotaxime | 7 | 2 | 5 | – |
| Cefixime | 23 | 20 | 18 | p = 0.02 |
| Meropenem | 8 | 2 | 4 | – |
| Beta lactam/inhibitor | 22 | 9 | 4 | – |
| Quinolones | 12 | 5 | 3 | – |
| Macrolides | 15 | 2 | 5 | – |
| Urinary anti-septic | 4 | – | – | – |
| Glycopeptides | 2 | – | 4 | – |
| Current episode | ||||
| Duration of illness prior to seek care (hours ± SD) | 8 ± 4 | 12 ± 3 | 22 ± 6 | p < 0.05 |
| Mode of initial treatment consultation of | ||||
| GP—local medical practitioner | 23 | 24 | 24 | |
| Consultant pediatrician | 45 | 11 | 21 | p < 0.05 |
| Empirical antimicrobial prescription rate (%) | 100% | 100% | 100% | – |
| UFR done (n) | 34 | 24 | 26 | – |
| Urine culture done (n) | 22 | 12 | 12 | – |
| Culture positive (n) | 16 | 9 | 8 | – |
| Duration of treatment (hours ± SD) | 18 ± 4 h | 20 ± 3 h | 25 ± 8 h | – |
| Inward care | ||||
| Period taken to inward care following GP care | 20 ± 4.4 h | 22 ± 4.6 h | 28 ± 4 h | – |
| Inward Urine culture done | 100% | 100% | 100% | – |
| Inward Urine culture positivity (%) | 31.4% | 36.8% | 32.2% | – |
| Change of prescribed antimicrobials | ||||
| Escalation | 80% | 88% | 92% | p = 0.02 |
| De-escalation | 16% | 6% | 4% | – |
| Not changed | 4% | 6% | 4% | – |
| Out come | ||||
| Hospital stay (mean days ± SD) | 3 ± 1 | 3.5 ± 0.5 | 4 ± 0.8 | – |
| Complications | ||||
| Septicemia | 5 | 3 | 5 | – |
| Renal abscess | 4 | 4 | 4 | – |
| Infective endocarditis | 2 | 4 | 4 | – |
| USS-abdomen | ||||
| Normal | 90 | 50 | 44 | p = 0.02 |
| Pyelonephritis | 16 | 5 | 6 | |
| Structural anomalies | ||||
| Scaring | 2 | 2 | 3 | – |
| Follow up detail in next 18-month period | ||||
| Frequency of UTI per year | 1.5 ± 1 | 1 ± 1 | 2 ± 1 | – |
| Compliance rate of antimicrobial use | ||||
| First day | 100% | 100% | 100% | – |
| Completion of dosage | 60 ± 10% | 50 ± 10% | 52 ± 10% | – |
| Average cost for antimicrobials (LKR) | ||||
| 1st episode | 88 ± 12 | 112 ± 20 | 132 ± 54 | – |
| Total in last 24 months | 1200 ± 300 | 1300 ± 280 | 1660 ± 290 | – |
UTI urinary tract infections, ARTI acute respiratory tract infection, AGE acute gastro enteritis; Infection in CNS central nervous system infections, IE infective endocarditis, ICU intensive care unit
Fig. 1Fractions of E. coli and K. pneumoniae positive isolates and subsequent emergence of ESBL E. coli and K. pneumoniae over 24 months in 6 month intervalsin same cohort. a Fraction of E.coli positive isolates over 24 months in 6 month intervals. b Fraction of K. pneumoniae positive isolates over 24 months in 6 month intervals. c Fraction of ESBL-E.coli positive isolates over 24 months in 6 month intervals. d Fraction of ESBL-K. pneumoniae positive isolates over 24 months in 6 month intervals
Antibiotic Susceptibilities of ESBL-Producing isolates
| Antibiotic sensitivity | ESBL | |
|---|---|---|
| Meropenem | 126 (96) | 86 (96.6) |
| Piperacillin/tazobactam | 76 (59.8) | 52 (58.4) |
| Amikacin | 115 (90.5) | 80 (89.5) |
| Gentamycin | 22 (17.3) | 12 (13.4) |
| Ciprofloxacin | 8 (6.2) | 6 (6.7) |
| Trimethoprim/sulphamethoxazole | 24 (18.9) | 23 (25.8) |
| Nitrofurantoin | 38 (30) | 12 (13.4) |
ESBL Extended spectrum of beta lactamases
Demography and clinical presentation of subjects having renal scarring with UTI recurrences
| Subjects with recurrent UTI (n = 36) | |||
|---|---|---|---|
| Renal scarring (n = 22) | No renal scarring (n = 14) | p value | |
| Age at presentation (mean ± SD year) | 3.5 ± 0.9 | 1.9 ± 0.7 | > 0.05 |
| Gender (male: female) | 14:4 | 11:7 | 0.04 |
| UTI frequency (mean ± SD per year) | 3.5 ± 0.3 | 1.7 ± 0.5 | 0.04 |
| Type of UTI | |||
| Pyelonephritis | 22 (100%) | 10 (71.4%) | 0.03 |
| Other UTIs | 0 | 4 (38.6%) | 0.03 |
| Biofilm formation in patients with pyelonephritis | |||
| | 16 (72.7%) | 6 (42.8%) | 0.04 |
| | 6 (27.3%) | 2 (14.3%) | 0.04 |
| Vesico-ureteral reflux | 4 (18.2%) | 2 (19.3%) | > 0.05 |
p < 0.05 considered as significant